# BRAIDWELL LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1920938. Source: https://holderbook.com/funds/1920938-braidwell-lp/

- Reported value: $2.7B
- Positions: 86
- Weight of the ten largest: 31.6%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| CARIS LIFE SCIENCES INC | [CAI](https://holderbook.com/stocks/CAI/) | $147.1M | 8,256,032 | 5.4% | 5 |
| HINGE HEALTH INC | [HNGE](https://holderbook.com/stocks/HNGE/) | $110.4M | 1,330,127 | 4.1% | 4 |
| GLAUKOS CORP | [GKOS](https://holderbook.com/stocks/GKOS/) | $82.7M | 591,927 | 3.1% | 15 |
| EDGEWISE THERAPEUTICS INC | [EWTX](https://holderbook.com/stocks/EWTX/) | $81.1M | 1,996,965 | 3.0% | 8 |
| SPYRE THERAPEUTICS INC | [SYRE](https://holderbook.com/stocks/SYRE/) | $78.1M | 879,467 | 2.9% | 11 |
| IRHYTHM HOLDINGS INC | [IRTC](https://holderbook.com/stocks/IRTC/) | $77.8M | 654,262 | 2.9% | 15 |
| NEOGENOMICS INC | [NEO](https://holderbook.com/stocks/NEO/) | $71.8M | 4,918,202 | 2.7% | 4 |
| KODIAK SCIENCES INC | [KOD](https://holderbook.com/stocks/KOD/) | $69.6M | 1,787,318 | 2.6% | 3 |
| XENON PHARMACEUTICALS INC | [XENE](https://holderbook.com/stocks/XENE/) | $68.3M | 1,131,452 | 2.5% | 15 |
| ALPHATEC HLDGS INC | - | $66.2M | 69,121,000 | 2.4% | 2 |
| MONTE ROSA THERAPEUTICS INC | [GLUE](https://holderbook.com/stocks/GLUE/) | $59.3M | 2,451,562 | 2.2% | 3 |
| DIANTHUS THERAPEUTICS INC | [DNTH](https://holderbook.com/stocks/DNTH/) | $58.0M | 594,562 | 2.1% | 4 |
| NEUROCRINE BIOSCIENCES INC | [NBIX](https://holderbook.com/stocks/NBIX/) | $56.7M | 336,171 | 2.1% | 14 |
| ALPHATEC HLDGS INC | [ATEC](https://holderbook.com/stocks/ATEC/) | $56.5M | 6,531,439 | 2.1% | 2 |
| GENERATE BIOMEDICINES INC | [GENB](https://holderbook.com/stocks/GENB/) | $55.4M | 3,283,844 | 2.0% | 2 |
| MARAVAI LIFESCIENCES HLDGS I | [MRVI](https://holderbook.com/stocks/MRVI/) | $54.3M | 8,702,921 | 2.0% | 13 |
| KRYSTAL BIOTECH INC | [KRYS](https://holderbook.com/stocks/KRYS/) | $47.9M | 128,975 | 1.8% | 15 |
| HUMANA INC | [HUM](https://holderbook.com/stocks/HUM/) | $45.5M | 114,500 | 1.7% | 1 |
| THERMO FISHER SCIENTIFIC INC | [TMO](https://holderbook.com/stocks/TMO/) | $44.8M | 89,395 | 1.7% | 7 |
| KYMERA THERAPEUTICS INC | [KYMR](https://holderbook.com/stocks/KYMR/) | $43.4M | 378,163 | 1.6% | 4 |
| RHYTHM PHARMACEUTICALS INC | [RYTM](https://holderbook.com/stocks/RYTM/) | $42.3M | 381,128 | 1.6% | 2 |
| DAMORA THERAPEUTICS INC | [DMRA](https://holderbook.com/stocks/DMRA/) | $42.1M | 1,620,377 | 1.6% | 2 |
| ACADIA PHARMACEUTICALS INC | [ACAD](https://holderbook.com/stocks/ACAD/) | $41.7M | 1,646,399 | 1.5% | 4 |
| BRIGHTSPRING HEALTH SVCS INC | [BTSG](https://holderbook.com/stocks/BTSG/) | $41.6M | 596,753 | 1.5% | 3 |
| TRANSMEDICS GROUP INC | [TMDX](https://holderbook.com/stocks/TMDX/) | $40.5M | 609,715 | 1.5% | 7 |
| MBX BIOSCIENCES INC | [MBX](https://holderbook.com/stocks/MBX/) | $39.2M | 710,880 | 1.5% | 3 |
| CLIMB BIO INC | [CLYM](https://holderbook.com/stocks/CLYM/) | $36.5M | 2,797,375 | 1.3% | 2 |
| CAREDX INC | [CDNA](https://holderbook.com/stocks/CDNA/) | $34.8M | 1,220,602 | 1.3% | 4 |
| MAZE THERAPEUTICS INC | [MAZE](https://holderbook.com/stocks/MAZE/) | $34.0M | 1,140,040 | 1.3% | 1 |
| BRIGHT MINDS BIOSCIENCES INC | [DRUG](https://holderbook.com/stocks/DRUG/) | $34.0M | 483,822 | 1.3% | 4 |
| ACADIA HEALTHCARE COMPANY IN | [ACHC](https://holderbook.com/stocks/ACHC/) | $33.7M | 1,141,477 | 1.2% | 2 |
| NEKTAR THERAPEUTICS | [NKTR](https://holderbook.com/stocks/NKTR/) | $33.1M | 473,617 | 1.2% | 2 |
| CORVUS PHARMACEUTICALS INC | [CRVS](https://holderbook.com/stocks/CRVS/) | $31.8M | 2,126,298 | 1.2% | 2 |
| NURIX THERAPEUTICS INC | [NRIX](https://holderbook.com/stocks/NRIX/) | $31.2M | 1,286,769 | 1.2% | 3 |
| INSPIRE MED SYS INC | [INSP](https://holderbook.com/stocks/INSP/) | $30.2M | 677,570 | 1.1% | 12 |
| AVALO THERAPEUTICS INC | [AVTX](https://holderbook.com/stocks/AVTX/) | $30.1M | 1,629,182 | 1.1% | 1 |
| ALAMAR BIOSCIENCES INC | [ALMR](https://holderbook.com/stocks/ALMR/) | $29.4M | 1,083,983 | 1.1% | 1 |
| DANAHER CORP DEL | [DHR](https://holderbook.com/stocks/DHR/) | $28.7M | 150,627 | 1.1% | 6 |
| INTUITIVE SURGICAL INC | [ISRG](https://holderbook.com/stocks/ISRG/) | $27.9M | 70,137 | 1.0% | 10 |
| ORUKA THERAPEUTICS INC | [ORKA](https://holderbook.com/stocks/ORKA/) | $26.5M | 278,164 | 1.0% | 1 |
| AVALYN PHARMACEUTICALS INC | [AVLN](https://holderbook.com/stocks/AVLN/) | $26.4M | 801,395 | 1.0% | 1 |
| AVEANNA HEALTHCARE HLDGS INC | [AVAH](https://holderbook.com/stocks/AVAH/) | $26.3M | 3,065,106 | 1.0% | 2 |
| BIOAGE LABS INC | [BIOA](https://holderbook.com/stocks/BIOA/) | $25.3M | 1,033,129 | 0.9% | 2 |
| BOSTON SCIENTIFIC CORP | [BSX](https://holderbook.com/stocks/BSX/) | $25.1M | 587,567 | 0.9% | 2 |
| VERA THERAPEUTICS INC | [VERA](https://holderbook.com/stocks/VERA/) | $24.2M | 564,724 | 0.9% | 4 |
| REPLIGEN CORP | [RGEN](https://holderbook.com/stocks/RGEN/) | $24.2M | 177,100 | 0.9% | 13 |
| ZURA BIO LTD | [ZURA](https://holderbook.com/stocks/ZURA/) | $23.5M | 3,980,295 | 0.9% | 8 |
| GUARDANT HEALTH INC | [GH](https://holderbook.com/stocks/GH/) | $22.2M | 147,850 | 0.8% | 2 |
| EVOLUS INC | [EOLS](https://holderbook.com/stocks/EOLS/) | $21.9M | 3,155,209 | 0.8% | 3 |
| NATERA INC | [NTRA](https://holderbook.com/stocks/NTRA/) | $21.6M | 79,500 | 0.8% | 3 |
| ORTHOPEDIATRICS CORP | [KIDS](https://holderbook.com/stocks/KIDS/) | $21.1M | 1,100,370 | 0.8% | 15 |
| ELEVANCE HEALTH INC FORMERLY | [ELV](https://holderbook.com/stocks/ELV/) | $20.9M | 53,960 | 0.8% | 2 |
| TECTONIC THERAPEUTIC INC | [TECX](https://holderbook.com/stocks/TECX/) | $20.5M | 596,900 | 0.8% | 4 |
| DYNE THERAPEUTICS INC | [DYN](https://holderbook.com/stocks/DYN/) | $20.5M | 921,598 | 0.8% | 7 |
| NEOGENOMICS INC | - | $16.9M | 18,011,000 | 0.6% | 15 |
| IMMUNOCORE HLDGS PLC | [IMCR](https://holderbook.com/stocks/IMCR/) | $16.6M | 521,327 | 0.6% | 1 |
| REPLIGEN CORP | - | $16.4M | 16,000,000 | 0.6% | 7 |
| ARGENX SE | [ARGX](https://holderbook.com/stocks/ARGX/) | $16.4M | 17,707 | 0.6% | 11 |
| CELLDEX THERAPEUTICS INC NEW | [CLDX](https://holderbook.com/stocks/CLDX/) | $16.2M | 436,646 | 0.6% | 4 |
| OVID THERAPEUTICS INC | [OVID](https://holderbook.com/stocks/OVID/) | $15.9M | 5,919,464 | 0.6% | 1 |
| MANNKIND CORP | [MNKD](https://holderbook.com/stocks/MNKD/) | $14.7M | 3,458,429 | 0.5% | 1 |
| UNIQURE NV | [QURE](https://holderbook.com/stocks/QURE/) | $13.9M | 301,652 | 0.5% | 1 |
| X4 PHARMACEUTICALS INC | [XFOR](https://holderbook.com/stocks/XFOR/) | $13.6M | 2,922,754 | 0.5% | 3 |
| ORIC PHARMACEUTICALS INC | [ORIC](https://holderbook.com/stocks/ORIC/) | $13.2M | 1,214,540 | 0.5% | 2 |
| KINIKSA PHARMACEUTICALS INTL | [KNSA](https://holderbook.com/stocks/KNSA/) | $11.8M | 183,822 | 0.4% | 9 |
| OCULIS HOLDING AG | [OCS](https://holderbook.com/stocks/OCS/) | $11.6M | 834,183 | 0.4% | 1 |
| ACLARIS THERAPEUTICS INC | [ACRS](https://holderbook.com/stocks/ACRS/) | $11.3M | 2,142,348 | 0.4% | 2 |
| SEAPORT THERAPEUTICS INC | [SPTX](https://holderbook.com/stocks/SPTX/) | $10.9M | 500,000 | 0.4% | 1 |
| VOR BIOPHARMA INC | [VOR](https://holderbook.com/stocks/VOR/) | $10.6M | 573,104 | 0.4% | 2 |
| SURROZEN INC | [SRZN](https://holderbook.com/stocks/SRZN/) | $10.1M | 390,753 | 0.4% | 5 |
| IMMUNIC INC | [IMUX](https://holderbook.com/stocks/IMUX/) | $9.9M | 645,010 | 0.4% | 1 |
| HELIX ACQUISITION CORP III | [HLXC](https://holderbook.com/stocks/HLXC/) | $9.5M | 900,000 | 0.4% | 2 |
| IONIS PHARMACEUTICALS INC | [IONS](https://holderbook.com/stocks/IONS/) | $9.3M | 116,762 | 0.3% | 2 |
| QUEST DIAGNOSTICS INC | [DGX](https://holderbook.com/stocks/DGX/) | $9.2M | 43,200 | 0.3% | 1 |
| ADLAI NORTYE LTD | [ANL](https://holderbook.com/stocks/ANL/) | $9.1M | 795,214 | 0.3% | 1 |
| TENAX THERAPEUTICS INC | [TENX](https://holderbook.com/stocks/TENX/) | $8.5M | 584,412 | 0.3% | 1 |
| KARDIGAN INC | [KARD](https://holderbook.com/stocks/KARD/) | $7.2M | 300,000 | 0.3% | 1 |
| AMANAT ACQUISITION CORP | [AMAN](https://holderbook.com/stocks/AMAN/) | $7.1M | 700,000 | 0.3% | 1 |
| HEMAB THERAPEUTICS HLDGS INC | - | $5.9M | 160,000 | 0.2% | 1 |
| GH RESEARCH PLC | [GHRS](https://holderbook.com/stocks/GHRS/) | $5.6M | 207,240 | 0.2% | 1 |
| WATERS CORP | [WAT](https://holderbook.com/stocks/WAT/) | $5.3M | 14,040 | 0.2% | 1 |
| RESEARCH ALLIANCE CORP III | [RACC](https://holderbook.com/stocks/RACC/) | $4.3M | 400,000 | 0.2% | 1 |
| JATT II ACQUISITION CORP | - | $2.8M | 250,000 | 0.1% | 1 |
| PULMONX CORP | [LUNG](https://holderbook.com/stocks/LUNG/) | $978.3K | 752,541 | 0.0% | 15 |
| VYNE THERAPEUTICS INC | [VYNE](https://holderbook.com/stocks/VYNE/) | $596.1K | 916,077 | 0.0% | 2 |
| CYCLERION THERAPEUTICS INC | [CYCN](https://holderbook.com/stocks/CYCN/) | $531.9K | 156,890 | 0.0% | 1 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +24.7% | +14.8% | +9.9% | 84% |
| Q1 2026 | +0.4% | -4.6% | +5.0% | 82% |
| Q4 2025 | +18.7% | +2.4% | +16.4% | 73% |
| Q3 2025 | +14.1% | +7.8% | +6.3% | 72% |
| Q2 2025 | +5.3% | +10.5% | -5.1% | 67% |
| Q1 2025 | -15.7% | -4.6% | -11.1% | 66% |
| Q4 2024 | -7.0% | +2.1% | -9.1% | 66% |
| Q3 2024 | +9.4% | +5.4% | +4.0% | 61% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $2.7B | 86 |
| Q1 2026 | $3.0B | 88 |
| Q4 2025 | $3.1B | 73 |
| Q3 2025 | $3.4B | 73 |
| Q2 2025 | $2.9B | 55 |
| Q1 2025 | $2.8B | 64 |
| Q4 2024 | $3.4B | 73 |
| Q3 2024 | $3.5B | 81 |
| Q2 2024 | $3.2B | 75 |
| Q1 2024 | $3.1B | 70 |
| Q4 2023 | $2.7B | 72 |
| Q3 2023 | $3.2B | 85 |